Explore the Potential with AI-Driven Innovation
The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.
We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.
Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.
We use our state-of-the-art dedicated workflow for designing focused libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
It includes in-depth molecular simulations of both the catalytic and allosteric binding pockets, with ensemble virtual screening focusing on their conformational flexibility. For modulators, the process includes considering the structural shifts due to reaction intermediates to boost activity and selectivity.
Our library distinguishes itself through several key aspects:
partner
Reaxense
upacc
Q9Y5R2
UPID:
MMP24_HUMAN
Alternative names:
Membrane-type matrix metalloproteinase 5; Membrane-type-5 matrix metalloproteinase
Alternative UPACC:
Q9Y5R2; B7ZBG8; Q9H440
Background:
Matrix metalloproteinase-24, also known as Membrane-type matrix metalloproteinase 5, plays a pivotal role in neuro-immune interactions and neural stem cell regulation. It mediates the cleavage of N-cadherin, influencing peripheral thermal nociception, inflammatory hyperalgesia, and neural stem cell quiescence. Its activity extends to the modulation of cell-cell interactions, axonal growth, and the degradation of various proteoglycans.
Therapeutic significance:
Understanding the role of Matrix metalloproteinase-24 could open doors to potential therapeutic strategies.